Omega Funds co-leads Spruce Biosciences' $88M Series B

February 19, 2020Client News

In the announcement of the transaction Dina Chaya, Advisor to Omega Funds, said “We are impressed with the potential for tildacerfont to become the first approved treatment for patients with classic congenital adrenal hyperplasia around the world, as well as the encouraging positive results recently announced from its Phase 2 clinical trial. This drug could be a life-altering therapy for patients with CAH.”

The Gunderson Dettmer deal team was led by Jeffrey Engerman and included Kelvin Chan, Misola Ijidakinro and Andrew Weymouth.